Comparison of the effects of a cell saver and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing valve surgery.

OBJECTIVE To compare 2 important techniques of blood conservation, use of a cell saver and low-dose aprotinin, in terms of blood loss and homologous blood usage in patients undergoing cardiac valve surgery. DESIGN Prospective, randomized. SETTING Tertiary care hospital. PARTICIPANTS Sixty adult patients undergoing elective valve surgery. INTERVENTIONS The patients were divided into 3 groups of 20 each. In group 1, aprotinin in the dose of 30,000 KIU/kg was added to the pump prime, with a further dose of 15,000 KIU/kg added at the end of each hour of cardiopulmonary bypass. In group 2, a cell-saver system was used to collect all blood at the operation site for processing in preparation for subsequent reinfusion. Group 3 patients acted as a control group and underwent routine management, which included collection of autologous blood during the pre-cardiopulmonary bypass period. A hemoglobin of <8 g/dL was considered as an indication for bank blood transfusion in the postoperative period. MEASUREMENTS AND MAIN RESULTS The chest tube drainage was significantly less in group 1 compared with groups 2 and 3, with total drainage (median [interquartile range]) amounting to 250 mL [105 to 325 mL] vs. 700 mL [525 to 910 mL] in group 2 and 800 mL [650 to 880 mL] in group 3 (p < 0.001). The patients in groups 1 and 2 required significantly less bank blood (median [interquartile range]) as compared with group 3 (350 mL [0 to 525 mL], 350 mL [0 to 350 mL], and 1050 mL [875 to 1050 mL]; p < 0.001), respectively. Cell saver provided 410 +/- 130 mL of hemoconcentrated blood in group 2. The average preoperative hemoglobin concentration was 11.3 g/dL, and it was around 9 g/dL on the 7th postoperative day. The hemoglobin concentration at various stages during hospitalization in all 3 groups was similar. CONCLUSIONS Low-dose aprotinin and a cell saver are effective and comparable methods of blood conservation. Aprotinin helps by decreasing the postoperative drainage, and a cell saver helps by making the patient's own blood available for transfusion.

[1]  M. Prins,et al.  Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints , 1999, The Lancet.

[2]  J. Levy,et al.  Case 3--1999. Intraoperative coronary thrombosis in association with low-dose aprotinin therapy. , 1999, Journal of cardiothoracic and vascular anesthesia.

[3]  G. Escolar,et al.  Platelet function during cardiac surgery and cardiopulmonary bypass with low-dose aprotinin. , 1999, Journal of cardiothoracic and vascular anesthesia.

[4]  W. White,et al.  Cost‐Benefit and Efficacy of Aprotinin Compared with ε‐Aminocaproic Acid in Patients Having Repeated Cardiac Operations: A Randomized, Blinded Clinical Trial , 1997 .

[5]  P. Dryden,et al.  Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery. , 1997, Circulation.

[6]  M. Jochum,et al.  Long-term follow-up of aprotinin-specific immunoglobulin G antibodies after cardiac operations. , 1997, The Journal of thoracic and cardiovascular surgery.

[7]  H. Lummis,et al.  The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  S. Bélisle,et al.  Randomized, Placebo‐Controlled, Double‐Blind Study of an Ultra‐Low‐Dose Aprotinin Regimen in Reoperative and/or Complex Cardiac Operations , 1997, Journal of cardiac surgery.

[9]  L. Cohn,et al.  Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. , 1996, The Journal of thoracic and cardiovascular surgery.

[10]  D. Tempe,et al.  Blood conservation in small adults undergoing valve surgery. , 1996, Journal of cardiothoracic and vascular anesthesia.

[11]  R. E. Clark,et al.  A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. , 1995, Circulation.

[12]  S. Pugh,et al.  A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. , 1995, Journal of cardiothoracic and vascular anesthesia.

[13]  P. Brady,et al.  The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery. , 1995, Journal of cardiothoracic and vascular anesthesia.

[14]  J. Levy,et al.  Pharmacokinetics of Aprotinin in Preoperative Cardiac Surgical Patients , 1994, Anesthesiology.

[15]  C. Bailey,et al.  Randomised placebo controlled double blind study of two low dose aprotinin regimens in cardiac surgery. , 1994, British heart journal.

[16]  H. Redl,et al.  Formation of cytokines by retransfusion of shed whole blood. , 1994, British journal of anaesthesia.

[17]  D. Green,et al.  Effect of recombinant aprotinin on platelet activation in patients undergoing open heart surgery. , 1993, Haemostasis.

[18]  T. Misaki,et al.  Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[19]  E. Berreklouw,et al.  Low-dose aprotinin in internal mammary artery bypass operations contributes to important blood saving. , 1992, The Annals of thoracic surgery.

[20]  F. Loop,et al.  Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. , 1992, The Annals of thoracic surgery.

[21]  W. Dietrich,et al.  High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. , 1992, Journal of cardiothoracic and vascular anesthesia.

[22]  D. Royston High-dose aprotinin therapy: a review of the first five years' experience. , 1992, Journal of cardiothoracic and vascular anesthesia.

[23]  J. Soria,et al.  Hemostasis in Patients Undergoing Extracorporeal Circulation: The Effect of Aprotinin (Trasylol) , 1991, Thrombosis and Haemostasis.

[24]  L. V. von Segesser,et al.  Low-dose aprotinin also allows reduction of blood loss after cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.

[25]  M. Abdelnoor,et al.  Conventional blood conservation techniques in 500 consecutive coronary artery bypass operations. , 1991, The Annals of thoracic surgery.

[26]  J. E. Doran,et al.  Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. , 1991, The Journal of thoracic and cardiovascular surgery.

[27]  P. Fondu,et al.  Low-dose aprotinin for reduction of blood loss after cardiopulmonary bypass , 1991, The Lancet.

[28]  K. Otani,et al.  Lack of withdrawal symptoms after discontinuation of mianserin , 1991, The Lancet.

[29]  C. Soria,et al.  Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. , 1991, Blood.

[30]  F. Sebening,et al.  Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. , 1990, Anesthesiology.

[31]  W. van Oeveren,et al.  Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. , 1990, The Journal of thoracic and cardiovascular surgery.

[32]  J. Jones,et al.  Effects of intraoperative plasmapheresis on blood loss in cardiac surgery. , 1990, The Annals of thoracic surgery.

[33]  L. Donovan,et al.  Autologous blood donations prior to elective cardiac surgery. Safety and effect on subsequent blood use. , 1989 .

[34]  D. Cosgrove,et al.  Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). , 1989, The Journal of thoracic and cardiovascular surgery.

[35]  R. Mammana,et al.  Intraoperative autotransfusion in cardiac operations. Effect on intraoperative and postoperative transfusion requirements. , 1988, The Journal of thoracic and cardiovascular surgery.

[36]  W. van Oeveren,et al.  Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. , 1987, The Annals of thoracic surgery.

[37]  J. Rumberger,et al.  Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. , 1995, The Annals of thoracic surgery.

[38]  E. Covino,et al.  Low dose aprotinin as blood saver in open heart surgery. , 1991, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.